We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Angle Plc | LSE:AGL | London | Ordinary Share | GB0034330679 | ORD 10P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -0.25 | -1.06% | 23.25 | 2,441,026 | 09:33:55 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 23.00 | 23.50 | 25.00 | 22.50 | 24.25 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Business Services, Nec | 1.04M | -21.69M | -0.0832 | -2.82 | 61.24M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 09:36:11 | O | 25,000 | 23.50 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 03/5/2024 | 12:17 | ALNC |  CORRECT: Angle shares up on assay development deal with AstraZeneca |
| 03/5/2024 | 11:50 | ALNC | Angle shares up on assay development deal with AstraZenaca |
| 03/5/2024 | 07:00 | UK RNS | Angle PLC New commercial agreement with large pharma |
| 24/4/2024 | 10:32 | ALNC | Angle shares jump on supplier agreement with with AstraZeneca |
| 24/4/2024 | 07:00 | UK RNS | Angle PLC New commercial agreement with AstraZeneca |
| 22/4/2024 | 16:52 | ALNC | IN BRIEF: Angle granted patents in US and Europe for Cellkeep slide |
| 22/4/2024 | 07:00 | UK RNS | Angle PLC US and EU patents for innovative CellKeep™ slide |
| 08/4/2024 | 07:00 | UK RNS | Angle PLC Parsortix HER2 assay showcased at AACR 2024 |
| 22/3/2024 | 07:00 | UK RNS | Angle PLC Parsortix at European breast cancer conference |
| 22/1/2024 | 18:03 | ALNC | IN BRIEF: Angle highlights supportive data for DNA analysis tool |
Angle (AGL) Share Charts1 Year Angle Chart |
|
1 Month Angle Chart |
Intraday Angle Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 10/5/2024 | 09:15 | ANGLE PLC - 2019 THREAD - LIQUID BIOPSY COMPANY | 24,711 |
| 09/5/2024 | 09:23 | AGL has been Jinxed by the God of Shite. 10p Target | 235 |
| 12/2/2024 | 09:42 | Angle PLC | 660 |
| 29/1/2024 | 20:18 | ANGLE [12.75p] TARA*S SHARE OF THE DECADE "TARGET PRICE Ј100.00 PER SHARE." | 3,756 |
| 19/1/2024 | 11:27 | SHAREHOLDERS ACTION GROUP | 580 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 08:36:12 | 23.50 | 25,000 | 5,875.00 | O |
| 08:35:58 | 23.09 | 6,617 | 1,527.87 | O |
| 08:33:29 | 23.00 | 7,513 | 1,727.99 | O |
| 08:33:01 | 23.45 | 2,000 | 469.00 | O |
| 08:31:19 | 23.37 | 7,513 | 1,755.79 | O |
| Top Posts |
|---|
Posted at 05/5/2024 11:07 by purchaseatthetop “Maybe theybarneworried they are going to miss out and are trying to get on board at a lower entry price. Good luck with that next week lol”The reality is that nothing we post here has any impact on the share price. This is a place for discussion good or bad. The share price could certainly rise Monday but that will suit traders. The uplift would only be sustained with series of good news with numbers. |
Posted at 05/5/2024 10:59 by bones698 It's. Funny how posters from the past appear and talk it down when good news arrives and the share price strarts to move. Coincidence. The same few that have sold out in the past come back and try to get the share price down talking rubbish and spammming th thread constantly.Maybe theybarneworried they are going to miss out and are trying to get on board at a lower entry price. Good luck with that next week lol |
Posted at 04/5/2024 16:05 by bones698 Adw that's a fair post I get your concerns and have long held those fears with AGL.The thing is with a potential profits warning you elude to it would have come by now as berenberg forced them to issues them at the soonest possible oppurtunity in the past and the numbers with the 3 deals and kit sales etc look to be well. On track to deliver the revenue target. There is nothing in the price at these levels for the potential future earnings here especially when you consider how far they have come with products and contracts with big companies. They have restated q2 2025 several times now for cash runway, they are confident that is the case and even beyond depending on progress this year. I agree they will likely raise very late on this year or early next year but by then the share price will be higher given the news that is still to come from prostate and ovarian, thermo Fisher trial, talks with 11 other companies etc I think you got this call wrong but each to their own, If you dont like the risk sell that's fair enough. I just think at these levels there is a lot of bad news priced in given the progress made and as you know I have always been one of the most pessimistic when it comes to agl over the years. Gl whatever you decide to do I don't see many other companies in the position of agl out there with less risk and such potential that is now starting to deliver. |
Posted at 03/5/2024 13:44 by 5oletrader The 'CREW' which I believe is the 'SAME' from old conversing with one another using different alias's - are here for a reason!- Rebuttable:Want to know what MOTIVATION to NOT RAISE looks like? Mr NEWLAND having 7,179,686+ shares at £1.60 to the valuation of £11,487,497M plummet to the value of £717,968k at 10p. Mr NEWLAND having 1M share options that expire 09/11/2024. Vesting is subject to the performance conditions that a) the Company's share price must have increased to £2.00, £2.25, £2.50 and £2.75 at some point since the date of grant for each quarter of the allocation (this condition has not yet been met). Mr NEWLAND 'imv' attempting to signal to the market that shares were too cheap at 30p - buying 125,000 at 28.75p.Https://www.l |
Posted at 30/4/2024 20:18 by ohwhatfun KryptonAnd anyone also knows there is a mechanism to reduce the nominal value if they can’t get backers at 10p. The good news is the company value is not crazy. The bad is the likely cash level needed v the share price. If you have 260m shares in issue (MC £36m) at 14p and need £20m at 10p, that would mean 460m shares, say 11p open making the MC £50m, yet the burn is over 1m per month. So the claims of below 10p are not fantasy, countless AIM companies have seen share prices destroyed and diluted to oblivion in this market. Angle fortunately have something of apparent value, but years of lack of uptake will be used as leverage against them to push them lower. It’s a bad bargaining position start point. To be concluded in the coming weeks no doubt. Until it’s done everyday (without major deal news) is a gloomy day. Let’s hope results don’t have any, lower than expected, pushed into 2025 etc as the vultures will have even more discount ammo. |
Posted at 29/4/2024 07:39 by ohwhatfun GspannerThe news caught attention, some will have had AGL sat in the background waiting for interest/traction, lurking rather than avid followers. Check out the share price performance and confusing lack of interest in recent years in their tech. AZ prompt a look, time to buy? The deeper look shows last raise £20m in 2022 at 80p. Various forecasts of a cash runway, H2 2024 to Q1 25 to into Q2 25. The last business update included, slower than expected. The small cap market has been decimated, share prices obliterated, a mass of examples of angry investors where large discounts have been in play and share price collapses immediately before fund raises. Posts of yeah buy now big deal, but sensible, risk averse investors look at the full picture. AGL appear to have left it later in the day to raise funds than usual, perhaps hoping for a higher share price on the back of news. The market knows they need money, the market is highly risk averse, so if AGL go to market for funding, the market will drop the share price and discount from there. If 15p is to be the share price pre fund raise game, then a 10p raise would be generous. It’s just sober market opinions, unaffected by holding (loss or profits). Typically those shouting the loudest pumping, are looking for a quick exit, knowing the loitering cash issue will impact the share price. Chances of avoiding dilution are unknown, it’s a coin flip. How many avoid it is the best guide pretty much all have had major dilution with some failing to attract funding at all. That’s how some see it, it’s opinions based on the reality of the market. The chance of normal market behaviour on a fund raise for AGL, is high. |
Posted at 28/4/2024 14:23 by ohwhatfun Adw was wise to sell at 16p given the funding need.Even if it now went up to 25p +50%… why? In any raise the more buyers you have the better it is for MMs, they raise the price, fomo kicks in and they forward sell into the demand. They square up in the raise. So even if it hit 25p on the fomo, many would sell, but they key point is during the raise period, the city know and they drag the price down, turning the screw on the company on the placing price. Whenever the raise comes (if via the market) a noticeable share price fall (often inexplicable to posters) will appear. Then it’s discounted from there. So Adw would get back in under 16p in that scenario. Plenty of examples put there, EG just about every small cap that has raised funds this last year or so. Results typically about now these last few years, so perhaps next week. Watch out for the share price behaviours mentioned, it’s a solid sign that a raise is in play |
Posted at 27/4/2024 07:49 by bones699 Financials when eventually released will look diasterous and no doubt the focus will be on cash burn and likely placement with the share price no doubt crashing 20% or more on results release day..The RNS's look like a desperate ramping attempt to pre empt the poor results and likely cash raise to try and keep the share price up to minimise share holder dilution...sub 10p cash placement now firmly on the cards and RNS's spouting tiny £150k deals don't cut the mustard imho!.. Newlands finger wagging £6m additional revenues needed to extend the cash run way till Q2 next year now look like nothing more than hot air and bluster! |
Posted at 27/4/2024 07:42 by ohwhatfun News caught attention but the doomsayers look right. It’s good to see such warnings of earnings forecast failures and pending results. It protects against blind buying on newsMore on the point of the savage market than AGL prospects. The doom side prompts fact checking. Interims warned of a slowing market, revenue not hit. Cost savings if achieved take cash INTO Q2 IE in reality is the end Q1, WITH the savings. The slowing market or incomplete savings could mean end of Q4. Funding typically to be at least 6 months min before the cash runs out. So either way by the end of June or up to Sept. Results out last year April 21, any funding likely to come after results. It appears from posts and slowing revenue that a missed forecast is in play, which will be in news to come. Probabilities from prior news and lack of revenue support a missed forecast and likely a raise before the end of June, likely post results. Raise at a post share price drop, market manipulation game. That game includes raising the share price to forward sell to retail investors, then drag it back in knowledge of the fund raise and close out their position in the raise. So with the known news, likely missed forecasts and a predictable timeline to raise funds, it’s looks like a very bad call to buy now. I see the £150k comment mentioned as irrelevant. It is not irrelevant in terms of cash in the bank and the likely impact on the fund raise price. Potential backers will use the derisory amount as leverage. Time will tell but on balance the doom crew crew have the best argument, based on the information available and market circumstances. Sadly a 10p raise or lower is likely. |
Posted at 24/4/2024 09:31 by sicilian_kan jelenko, hopefully they will have enough small customers, but I am going to await the financials before increasing my holding, as last year that was not the case. I don't think anyone is suggesting they will not be around. The issue is whether they need to dilute and if so the cost of that to us shareholders in terms of share price and dilution. At the moment, the share price is rightfully on the up. But if we get a revenue warning at any stage, we will see a sharp reversal. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
